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Resumo 
 Introdução: A terapia de ressincronização cardíaca (CRT) é um pilar no tratamento 
de pacientes com insuficiência cardíaca (HF).  Não obstante, a taxa de não resposta pode 
alcançar os 30% em algumas coortes.  A HF com frequência complica com o 
desenvolvimento de hipertensão pulmonar (PH) e disfunção do ventrículo direito (RV). 
Índices de função do RV e do seu acoplamento à artéria pulmonar (acoplamento RV-PA), 
nomeadamente o rácio entre a excursão sistólica do plano do anel tricúspide (TAPSE) e a 
pressão sistólica da artéria pulmonar (PASP), ambos obtidos ecocardiograficamente, tem 
sido proposto como marcador prognóstico na HF. Assim, os objetivos deste trabalho foram 
explorar as correlações clínicas e o valor prognóstico do acoplamento RV-PA em pacientes 
submetidos a CRT. 
Métodos: Num estudo unicêntrico, uma população inicial de 207 pacientes com HF 
submetidos a CRT foram rastreados retrospetivamente, tendo em conta as suas variáveis 
demográficas, clínicas, bioquímicas, ecocardiográficas, e seus resultados face a esta 
terapia. A mortalidade por todas as causas foi considerada como resultado primário, 
enquanto a melhoria clínica e ecocardiográfica, 6 a 12 meses após CRT, foram 
consideradas resultados secundários. 
 Resultados: Da população inicialmente rastreada, 69 pacientes apresentavam 
valores TAPSE e PASP. O período médio de seguimento foi de 42,2 meses; a mortalidade 
a um e a cinco anos foi de 99,3% e 64,8%, respetivamente. A sobrevida foi 
significativamente inferior em pacientes com PH (sobrevida a cinco anos de 57.9% vs 
71,3% para os pacientes sem PH). Os pacientes apresentaram uma fração de ejeção 
ventricular esquerda reduzida (LVEF) (26±7%); e 76,8% deles encontravam-se em classe 
III da escala New York Heart Association (NYHA). A CRT melhorou a LVEF (D ≥ 5%) e a 
NYHA (D ≥ 1) em 69,6% e 46,1% dos pacientes, respetivamente. De acordo com os tercis 
de TAPSE/PASP, não foram encontradas diferenças significativas entre as variáveis 
demográficas, clínicas, bem como na medicação de base. Os pacientes “não 
respondedores” à CRT tendencialmente apresentaram menores rácios TAPSE/PASP. A 
LVEF foi significativamente inferior em pacientes com rácios inferiores de TAPSE/PASP. 
Alterações estruturais do RV e do ventrículo esquerdo (LV) foram significativamente 
associadas com este rácio. Ao contrário da TAPSE e da TAPSE/PASP, a PASP 
demonstrou estar significativamente relacionada com o resultado primário, mesmo após 
ajuste multivariável [relação de risco (HR) de 1.019; intervalo de confiaça a 95% (CI) 0.994–
1.045; p=0,025]. Valores elevados de PASP e baixos de TAPSE/PASP encontraram-se 
significativamente associados a menores a melhorias da LVEF. A TAPSE/PASP 
correlacionou-se negativamente com os níveis plasmáticos de NT-proBNP e com o rácio 
da velocidade diastólica (E) do fluxo mitral e a velocidade diastólica (e’) do anel mitral (E/e’). 
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A TAPSE/PASP demonstrou melhor valor prognóstico em pacientes que não melhoraram 
a sua LVEF após a CRT (76,2% de sensibilidade e 70,8% de especificidade), 
comparativamente com a medição isolada da PASP ou TAPSE.   
 Conclusões: O rácio TAPSE/PASP correlacionou-se com marcadores de 
prognóstico validados na HF, tais como o NT-proBNP, a LVEF e o rácio E/e’.  Este novo 
índice ecocardiográfico superou a TAPSE, como medida isolada, na identificação de 
pacientes que não responderam à CRT.  
Palavras-chave 
Terapia de Ressincronização Cardíaca; Insuficiência Cardíaca; Circulação 
Pulmonar; Ventrículo Direito 
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Abstract 
 Introduction: Cardiac resynchronization therapy (CRT) is a mainstay treatment of 
heart failure (HF) patients. However, its nonresponse rate goes up to 30% in some cohorts. 
HF often complicates with pulmonary hypertension (PH) and right ventricle (RV) 
dysfunction. Indexes of RV function and its coupling to pulmonary artery (RV-PA coupling), 
namely the ratio between echo-derived tricuspid annular plane systolic excursion (TAPSE) 
and pulmonary artery systolic pressure (PASP) has been proposed as a prognostic marker 
of HF. We aim to explore the clinical correlates and prognostic value of RV-PA in patients 
with HF undergoing CRT. 
 Methods: We screened retrospectively an initial population of 207 patients with HF 
undergoing CRT, regarding demographic, clinical, biochemical, echocardiographic and 
outcome data. The primary outcome was all-cause mortality; secondary outcomes were 
improvement of clinical and echocardiographic markers after 6 to 12-months of CRT.  
 Results: Of the initial population screened, TAPSE and PASP variables were 
available in 69 patients. The average follow-up period were 42,2 months; one and five-year 
survival was 99.3% and 64.8%, respectively. Survival was significantly lower in patients with 
PH (five-year survival 57.9% vs 71.3% without PH). Patients had reduced left ventricular 
ejection fraction (LVEF) (26.4±7.1%); and 76,8% of patients were in New York Heart 
Association (NYHA) class III. CRT improved LVEF (D ≥ 5%) and NYHA (D ≥ 1) in 69,6% 
and 46,1% of patients, respectively. According TAPSE/PASP tertiles, no significant 
differences were found among demographic, clinical, and medication variables. 
Nonresponders to CRT trended to have lower TAPSE/PASP. LVEF was significantly lower 
in patients with lower TAPSE/PASP. Structural changes of both RV and LV chambers were 
also significantly associated with this ratio. PASP, but not TAPSE and TAPSE/PASP, were 
significantly related with primary outcome, even after multivariable adjustment [hazard ratio 
(HR) 1.019; 95% confidence interval (CI) 0.994–1.045; p=0,025]. Higher PASP or lower 
TAPSE/PASP ratio were significantly associated in LVEF improvement ≥ 5%. 
TAPSE/PASP was negatively correlated with plasmatic NT-proBNP levels and ratio 
between early ventricular wave filing (E) and early myocardial velocity (E’) (E/e’). 
TAPSE/PASP had better accuracy (76.2% sensitivity and 70.8% specificity) than single 
measurement of PASP or TAPSE in predicting patients with unimproved LVEF after CRT. 
 Conclusions: TAPSE/PASP ratio did correlate with validated prognostic markers in 
HF such as NT-proBNP, LVEF and E/e’. This new echo-derived index outperformed isolated 
TAPSE in identifying patients who did not respond to CRT.  
Keywords 
Cardiac Resynchronization Therapy; Heart Failure; Pulmonary Circulation; Right 
Ventricle  
 v 
List of abbreviations 
 
BMI Body mass index 
COPD Chronic Obstructive Pulmonary Disease 
CRT Cardiac Resynchronization Therapy 
CRT-D Cardiac Resynchronization Therapy Defibrillator 
E/e' Early ventricular wave filing (E) and early myocardial velocity (e’) ratio 
GFR Glomerular Filtration Rate 
HF Heart Failure 
LA Left Atria 
LHD Left Heart Disease 
LV Left Ventricle 
LVEF Left Ventricular Ejection Fraction 
NS non significat 
NT-proBNP N-Terminal pro B-type Natriuretic Peptide  
NYHA New York Heart Association 
PA Pulmonary Artery 
PASP Pulmonary Artery Systolic Pressure  
PH Pulmonary Hypertension 
PVR Pulmonary Vascular Resistance 
RAP Right Atrial Pressure 
ROC Receiver Operating Characteristic 
RV Right Ventricle 
RVEDA Right Ventricle End-Diastolic Area 
RVESA Right Ventricle End-Systolic Area 
S' Tricuspid annular systolic velocity 
TAPSE Tricuspid Annular Plane Systolic Excursion 
TRV Tricuspid Regurgitant Velocity  
TVIROT Right ventricular Outflow Tract Time-Velocity Integral  
 
 
 
 
 
 
 
 
 
 
 
 
 vi 
 
 
Index 
 
Introduction ....................................................................................................................... 1 
Methods ............................................................................................................................ 2 
Results ............................................................................................................................. 3 
Discussion ........................................................................................................................ 5 
Conclusion ........................................................................................................................ 8 
Study limitations................................................................................................................ 8 
Appendix......................................................................................................................... 10 
References ..................................................................................................................... 16 
 
 
  
 vii 
List of tables 
 
Table 1 – Clinical features of the studied population according to TAPSE/PASP tertiles 10 
 
Table 2 - Echocardiographic characteristics of the studied population according to 
TAPSE/PASP tertiles ...................................................................................................... 11 
 
Table 3 – Survival analysis for echocardiographic variables ........................................... 11 
 
Table 4 – Hazard rations for secondary outcomes .......................................................... 14 
 
  
 viii 
List of figures 
 
Figure 1 - Pearson’s correlation analysis between TAPSE/PASP and log-transformed NT-
proBNP before CRT. ....................................................................................................... 11 
 
Figure 2 - Survival curves according to PASP, TAPSE and TAPSE/PASP ratio for primary 
outcome all-cause of death. ............................................................................................ 12 
 
Figure 3 - Percentage of patients with improved LVEF response by PASP, TAPSE and 
TAPSE/PASP (categorized by median) 6 to 12 months after CRT. ................................. 12 
 
Figure 4 - Mortality rate by PASP, TAPSE and TAPSE/PASP (categorized by median) 6 
to 12 months after CRT. .................................................................................................. 13 
 
Figure 5 - ROC curves for TAPSE, PASP and TAPSE/PASP to identify unimproved LVEF 
(defined as LVEF < 5%) after CRT. ................................................................................ 13 
 
Figure 6 - Survival curves according to absence or presence of pulmonary hypertension 
(PH) for primary outcome of all-cause death in all patients. ............................................ 14 
 
Figure 7- Survival curves according to absence or presence of pulmonary hypertension 
(PH) for primary outcome of all-cause death in patients with glomerular filtration rate 
(GFR) equal or higher, or lower than 60mL/min/1.73m2. ................................................. 15 
 1 
 
Introduction 
 
Heart failure (HF) is a clinical syndrome characterized by structural and functional 
changes in ventricular filling and blood ejection(1). Cardiac resynchronization therapy (CRT) 
is an effective treatment to symptomatic HF patients under optimized pharmacological 
therapy(2, 3). CRT response is sensitive to the nature of comorbid illness and also to patients’ 
medication(4). Unfortunately, up to one third of patients with advanced HF show little or no 
response to CRT(3, 5). Several studies had demonstrated that response to CRT is predicted 
by baseline right ventricle (RV) function(6, 7). However, post-hoc analyses of large 
randomized control trials have challenged this concept(8). The need to better identify the 
subset of patients who will respond to this effective, yet invasive and expensive treatment, 
is currently unmet. 
In patients with chronic left ventricle (LV) dysfunction, continuous backward 
transmission of left-side filling pressures to pulmonary circulation eventually leads to 
pulmonary hypertension (PH)(9). PH due to left-side heart disease (PH-LHD) represents the 
most common cause of PH(10). PH-LHD continuum begins with an increase in post-capillary 
lung circulation pressure secondary to either LV diastolic/systolic dysfunction or valvular 
disease. By mechanisms still not fully understood, the pulmonary venous chronic 
hypertension promotes maladaptive structural changes in lung vessels that further overload 
RV(9, 11). Regardless of the underlying mechanisms, the presence of PH independently 
signals worse prognosis(12). Likewise, RV dysfunction is an independent prognostic marker 
in HF(13). However, the RV is very sensitive to afterload, and the way we assess RV function 
in clinical practice reflect both RV contractility and PH (a determinant of RV afterload). 
Recently, some studies on HF patients suggested that combining measures of PH severity 
and RV function might better capture the RV-pulmonary artery (RV-PA) coupling than the 
isolated measures(14). The ratio between tricuspid annular plane systolic excursion (TAPSE) 
and pulmonary artery systolic pressure (PASP), or TAPSE/PASP, is an indirect estimate of 
RV-PA coupling but presents strong relation with more accurate invasive measures(15). As 
HF sets this ratio declines, along with a progressive loss of RV efficiency in its pumping 
function until becomes uncoupled from pulmonary circulation(15, 16). Nonetheless, 
uncoupling of RV-PA during HF progression is not so linear, and some patients can present 
moderate to severe PH without major RV dysfunction(17).  The clinical meaning of these new 
RV-PA coupling measures in HF patients undergoing CRT is still unknown. 
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Therefore, we aimed to describe the clinical correlates of RV-PA coupling of HF patients 
undergoing CRT and examine its predictive ability regarding response to CRT and all-cause 
mortality.  
 
Methods 
 
A retrospective, single-center, study was conducted in 207 patients with HF 
submitted to CRT between 2012-2017 at Hospital Santo António/Centro Hospitalar do 
Porto. The study was approved by the Research Ethics Committee of Hospital Santo 
António/Centro Hospitalar do Porto (reference number: 2018.055[051-DEFI/051-CES]). 
Patient demographic, clinical and echocardiographic data before and after CRT 
were collected by chart review. Patient population was analyzed with respect to age, sex, 
etiology of HF (ischemic vs non-ischemic) and comorbidities (diabetes, hypertension, 
chronic obstructive pulmonary disease [COPD], smoke, stroke, atrial fibrillation). Ischemic 
heart disease was diagnosed on the basis of previous myocardial infarction or significant 
coronary artery disease assessed by coronary arteriography. 
All patients were on optimized medical therapy for their HF according to current 
therapeutic guidelines(1). Patients enrolled in this study met standard criteria for CRT 
implantation(1). A 6 to 12-month period following CRT implantation were used to assess 
clinical and echocardiographic impact of this therapy. Biochemical analyses (serum 
creatinine, blood hemoglobin concentration, N-terminal pro hormone b-type natriuretic 
peptide [NT-proBNP]) were made at the hospital laboratory with standard methods. 
Glomerular filtration rate (GFR) was derivate from “CKD-EPI” equation(18) using the most 
recent value of serum creatinine before CRT implantation.  
Transthoracic echocardiography was performed by certified sonographers, using a 
commercial equipment (Phillips IE33 and CX50), according to current international 
recommendations (19). Left ventricular ejection fraction (LVEF) was calculated using the 
biplane Simpson method. The presence of PH was evaluated estimating PASP derived by 
right atrial pressure (RAP) and tricuspid regurgitant velocity (TRV) as follows: RAP + 
4(TRV)2 (20). We assumed RAP based on inferior vena cava measurements: normal 
respiratory variability and diameter>22mm, 3mmHg; impaired variability or diameter > 
22mm, 8 mmHg; impaired variability and diameter > 22mm, 15mmHg. PH was considered 
present when PASP was  > 40 mmHg by echocardiography(21). Ratio between early 
ventricular wave filing (E) and early myocardial velocity (e’) was used to evaluate diastolic 
function. The ratio between TRV and right ventricular outflow tract time-velocity integral 
(TVIRVOT) was used as marker of pulmonary vascular resistance (PVR)(22). The right ventricle 
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and pulmonary circulation function were assessed by measuring TAPSE and PASP. 
Complete baseline and 6 to 12-month follow-up after CRT with echocardiographic 
evaluation of both TAPSE and PASP measures were available in 69 of the initial 207 
patients. 
Continuous variables are shown as the mean ± standard deviation. Categorical 
variables are expressed as percentage of patients (%). The primary outcome was all-cause 
mortality. Cox proportional hazards model were used to assess the impact of baseline 
PASP on all-cause mortality. Cumulative survival was calculated using Kaplan-Meier model 
and compared between PASP, TAPSE and TAPSE/PASP tertiles. The end-point of survival 
analysis was all-cause death.  Logistic regression was used to study secondary outcomes, 
namely improvement of New York Heart Association (D NYHA≥1) functional class and 
increase of LVEF (D LVEF≥5%) at 6 to 12 month following CRT implantation.  Cox 
proportional hazards models or logistic regression were performed in both univariate and 
multivariate to assess the unadjusted and adjusted association of clinical and 
echocardiography features with age, sex and log (NT-proBNP). Coefficient of Pearson was 
used for correlations performed between PASP vs log(NT-proBNP) before CRT. Survival 
analyses were performed using Kaplan-Meier method and the log-rank test integrated in an 
Excel® based program(23). Receiver operator characteristic (ROC) curves were plotted for 
RV-PA variables TAPSE, PASP and TAPSE/PASP ratio, to determine area under the curve, 
specificity and sensitivity of the optimal cut-offs. 
Differences between groups were tested by using the chi-square test and two-way 
ANOVA, unless otherwise specified. All analyses were performed using STATA Statistical 
Software, (StataCorp, Texas, USA; version 15 for macOS). Data were plotted and graphed 
using GraphPad Prism (GraphPad Software, La Jolla California USA, 7.0a for macOS). A 
p value < 0.05 was considered statistically significant. 
 
 
Results 
 
Demographic and clinical characteristics of the 69 patients with available 
TAPSE/PASP (33.3 % of the initial population included in the study) are showed in table 1, 
according to TAPSE/PASP tertiles. Estimation of PASP was feasible in 119 patients (57 %) 
and TAPSE in 97 patients (47 %). Overall, patients had a mean age of 70±10 years, 70% 
were male, without any significant demographic differences between TAPSE/PASP tertiles. 
Overweight was found in all subgroups, with an overall body mass index (BMI) of 27±9 
kg/m2. A total prevalence of 42.0% diabetes, 79.7% arterial hypertension, 73.9% 
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dyslipidemia, 37.6% smoking history, 56.5% atrial fibrillation, 20.3% COPD and 10.1% 
stroke were found in this cohort. Among clinical characteristics studied, there were no 
significant differences between TAPSE/PASP subgroups. About half of patients (50.7%) 
had non-ischemic cardiomyopathy. Mostly patients submitted to CRT were in NYHA III class 
(76.8%), with left bundle block (79.3%) and mean GFR of 61.2±23.9 mL/min/1.73m2. 
Average QRS duration was 163±27 ms. All patients were under optimized medical therapy 
for HF, with no significant differences in medication between all subgroups. The majority of 
patients showed improvement of LVEF (69.6%), and 46.1% of them showed functional 
improvement (NYHA) with CRT. Lower TAPSE/PASP ratios were related with lower 
improvement of LVEF and a trended for NYHA improvement (table 1); NT-proBNP levels 
were negatively correlated with TAPSE/PASP (figure 1). Across TAPSE/PASP tertiles there 
was a significant change of hemoglobin levels (table 1). 
Baseline echocardiographic evaluation before CRT  
(table 2) showed that all patients enrolled in this study presented HF with reduced LVEF, 
with an overall LVEF of 26±7%, with lower levels present in subgroup with worse RV-PA 
coupling (first TAPSE/PASP tertile, p<0.05). Left atria (LA) chamber was found to be larger 
in groups with lower TAPSE/PASP (p<0.05), reaching an average area of 31±9 cm2 in the 
first tertile.  Mean right atrial (RA) area was 21±7 cm2 for all subgroups, with no significant 
differences between them. RV diameter, as well as RV end-diastolic area (RVEDA) and RV 
end-systolic area (RVESA), were found to be higher in patients with lower TAPSE/PASP 
(p<0.05). Regarding RV function, TAPSE was significantly lower in first TAPSE/PASP tertile 
(vs third tertile, p<0.05). PASP was significantly different across all subgroups.  Higher 
tricuspid annular systolic velocity (S’) was associated with higher TAPSE/PASP (p<0.05). 
Left ventricular filling pressures, estimated by E/e’, were higher in groups with lower 
TAPSE/PASP ratios (p<0.05). Higher PVR was significantly related with TAPSE/PASP.  
Other echocardiographic characteristics did not vary significantly within the range of 
TAPSE/PASP ratios.  
Patients were followed for a mean period of 42,2 months. During this time, 50 
patients died (24,0% of the initial population screened). One-year survival was 93.3% and 
five-year survival was 64.8%.  Survival was significantly higher in group with PASP below 
median, with one-year survival of 98.6% (vs 88.1% in group with PASP above median); 
five-year survival 71.3% (vs 57.9% in group with PASP above median) (figure 2A). 
According to definition of PH based on PASP, patients with PH presented higher one and 
fiver-year mortality (supplementary data, figure 6) Patients with compromised RV-PA 
coupling (TAPSE/PASP< 0.43 mm/mmHg) showed one-year survival of 91.4% and five-
year survival of 50.4%, without significant differences between group with preserved RV-
PA coupling (figure 2C).  Patients with PH with renal dysfunction (GFR < 60mL/min/1.73m2) 
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prior to CRT, which corresponds to stage 3 or higher)(18), had significantly lower survival 
rates when compared with patients without PH (supplementary data, figure 7).  
In dichotomous analysis of TAPSE, PASP and TAPSE/PASP ratio, based on 
median values for each variable, PASP below threshold was significantly associated with 
LVEF improvement (figure 3) and all cause of death (figure 4). TAPSE/PASP>0.43 
mm/mmHg was associated with higher percentage of patients that exhibited LVEF 
improvement (figure 3), but without significantly affecting mortality (figure 4). TAPSE per se 
was not associated with changes in either LVEF improvement or mortality (figures 3 and 4). 
In figure 5 is depicted ROC curve analysis for RV-PA variables addressed in this 
study for non-responders to CRT (LVEF improvement < 5%). Among them, TAPSE/PASP 
ratio demonstrated better accuracy to detect patients that did not show LVEF improvement 
to CRT. The best cut-off point for TAPSE/PASP was 0.44 mm/mmHg with a sensitivity and 
specificity of 76.2% and 70.8%, respectively. 
Cox regression analysis of echocardiographic RV-PA correlated for primary 
outcome are showed in table 3. Greater baseline PASP was a significant univariate 
predictor (p=0.012), that was retained in multivariate analysis (p=0.025). Other variables 
analyzed did not seem to be independent predictors of adverse events in this population 
(table 3). On multivariate analysis, both NYHA and LVEF improvement were not 
independently associated with better survival (supplementary data, table 4). 
 
 
Discussion 
 
CRT is an established treatment for selected HF patients (2, 3). Current indications 
for CRT try to identify patients most likely to benefit(1), but studies show that up to 30% of 
those do not experience significant improvement and are unnecessary exposed to inherent 
potential complications(24). In HF, indexes of RV dysfunction are major predictors of patients’ 
outcome. RV-PA coupling has recently emerged as a prognostic marker outcome in patients 
with HF(13), although doubts still remain about its predictive power as an isolated measure(8). 
Our study provides data on the RV function of patients with severe LV impairment 
undergoing CRT. We focused mainly on the evaluation of RV-PA coupling, by means of 
echocardiographic evaluation of TAPSE/PASP, as a surrogate marker of CRT response 
and patient’s clinical outcomes. 
The main findings of our study are the following. First, the demographic and clinical 
features of patients across RV-PA coupling spectrum did not differ significantly, except for 
hemoglobin and NT-proBNP levels. In contrast, biochemical and echocardiographic 
 6 
biomarkers associated with worse prognosis (increased NT-proBNP, reduced LVEF and 
increased E/e’) were related to an impaired RV-PA coupling. Second, assessment of RV 
function by TAPSE as an isolated measure didn’t have predictive value.  
In this study, neither TAPSE nor TAPSE/PASP were significantly associated with 
all-cause mortality, but isolated PASP did. During follow-up period, we presented 
cumulative one and five-year mortalities of about 4 and 35%, in agreement with other 
reports(25). Previous studies showed that between PASP and TAPSE, only PASP correlated 
with mortality (in a composite outcome with hospitalizations). Of note, TAPSE/PASP was a 
better predictor of all-cause mortality and heart failure hospitalizations than PASP itself(26). 
As pointed above, despite the wide range of PASP thresholds used to stratify the risk in HF 
patients with PH, data showed that PASP>40 mmHg was an independent predictor of 
mortality, in line with previous reports(27). Different HF phenotypes in the studied population 
might explain the poor correlation of both TAPSE/PASP and TAPSE with mortality. Guazzi 
and co-workers worked on a HF population with moderate to severe LV impairment and 
differentiated four RV-PA phenotypes, with prognostic impact. They found lower mortality 
rates in patients with preserved RV function, defined as TAPSE≥16 mm(17). Based on 
medians, we defined TAPSE<14 mm as a marker of RV dysfunction. Previous studies 
demonstrated that this cut-off has impact on prognosis of patients with HF(27-29). However, 
almost 80% of our patients had TAPSE ≥ 14 mm, which means that RV function was 
preserved or at least not severely compromised, and according to Guazzi’s classification, 
most patients included in TAPSE/PASP analysis probably belonged to lower mortality 
groups with preserved RV function(13, 17, 27). Another explanation is possibly related with 
TAPSE/PASP threshold defined in study that cannot fully exploit its prognostic power(14). 
The proportion of patients who responded to CRT (using the echocardiographic 
definition stated above) was reduced in those with more impaired RV-PA coupling. To our 
knowledge the predictive value of TAPSE/PASP ratio hasn’t been previously examined in 
the population with CRT. An agreement about definition of a “responder” to CRT was not 
reached, yet(24). Adding more complexity, some patients can be either later (12months or 
higher) or shorter responders (about 6 months), and that also has impact on outcome(30, 31). 
Several measures have been used to demonstrate response to CRT, namely functional 
(e.g. NYHA), quality-of-life, event-based, reverse remodeling (e.g. LVEF, LV dimensions), 
either used individually or as composite(24, 32). In this study, we looked for NYHA and LVEF 
improvement as measures of CRT response. Several authors suggested an increase of 5% 
or more in LVEF, as well as NYHA improvement (³1), as favorable responses to CRT(33-36). 
We observed that 69.6% of patients showed improved LVEF³ 5%, and 46.4% showed 
improved NYHA, 6 to 12-months after CRT. However, between these two outcomes, only 
LVEF improvement was associated with TAPSE/PASP. Other researchers documented 
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LVEF improvement in 60-70 % of patients following 3 to 6-month post-CRT(25, 37, 38).This 
suggests that reverse remodeling promoted by CRT is time-dependent(30, 39), and the 
increased proportion of responders in our study is possibly due to longer period of CRT 
follow-up. Interestingly, once reverse remodeling is achieved it remains stable and the 
etiology of HF loses impact in patients’ outcome(25, 39).  In a recent prospective study, LV 
remodeling, evaluated by cardiac catheterization following 6 months of CRT, demonstrated 
that higher RV-PA coupling ratios were correlated with positive LV remodeling and long-
term survival. Furthermore, RV-PA coupling remained the only independent hemodynamic 
predictor for the echo-defined response, among other clinical, echocardiographic and 
hemodynamic covariates, including those related with LV function(40). In agreement with this 
find, the PROSPECT trial demonstrated that several echocardiographic parameters, most 
of them related with LV desynchrony, did not improve power to predict clinical response to 
CRT(41). The value of several echocardiographic related with RV function, including TAPSE, 
strain, RV ejection fraction and RV fractional area change, in predicting response to CRT 
was recently challenged in a meta-analysis(42). In ROC curve analysis we observed a better 
predictive value with TAPSE/PASP for LVEF improvement, with a sensitivity and a 
specificity very similar to those presented in Schmeisser’s study (73.2% sensitivity and 
70.5% specificity) for RV-PA coupling ratio(40). Another study found that a cut-off point of 
TAPSE of 14 mm adds value in predicting  response to CRT but, as pointed by the authors, 
no single RV parameter was able to identify who are likely to respond to CRT(43). In our 
data, TAPSE was the weakest predictor of LVEF improvement. TAPSE translates the main 
apical displacement of tricuspid annulus but its evaluation alone might be insufficient 
because it’s a regional parameter with angle-dependency and it doesn’t account for load 
conditions which are of critical importance to RV function(26). With progressive systolic 
dysfunction there’s an increased use of Starling’s “heterometric adaptation” (with 
preservation of cardiac output though increased afterload)(27). This leads to the uncoupling 
of the RV from the PA and makes load conditions increasingly important to function. In the 
CRT population this scenario is very frequent. Therefore, combining the evaluation of 
contractility (estimated by TAPSE) with afterload (estimated by PASP) might increase 
accuracy in RV function evaluation in this subset of patients. Further studies are necessary 
to prove the clinical value and explore the potential role of TAPSE/PASP as another tool to 
identify those who will respond to CRT. 
Apart from echocardiographic parameters, other variables may predict 
outcome/response in patients with PH-LHD submitted to CRT. Etiology of HF, QRS 
morphology and duration, gender, heart rhythm, renal and lung diseases are known to 
influence response to CRT(24, 44-46). With exception of renal function, our study did not find 
any of these variables to be related with response to CRT and outcome. Baseline renal 
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function affected survival in the subgroup of patients with PH (PASP>40 mmHg). 
Nevertheless, this result expands and strengthens the notion that RV dysfunction and CKD 
are associated with a poor outcome in chronic systolic HF(4, 15, 46, 47). 
In our population, TAPSE/PASP was significantly associated with robust prognostic 
surrogate markers in HF such as baseline LVEF, increased E/e’ and NT-proBNP plasma 
concentrations. Comparably to our data, Guazzi’s study demonstrated that nonsurvivors 
patients with HF had poorer LV function (lower baseline LVEF, higher plasmatic NT-
proBNP, and higher E/e’); and also poor RV function (lower TAPSE, higher PASP and, 
therefore, lower TAPSE/PASP ratio)(14). The levels of BNP or its prohormone are mostly 
used to stratify risk in patients in LV failure. Yet, these natriuretic peptides also correlate 
with right heart circulation (48). The inverse relation observed between TAPSE/PASP and 
NT-proBNP levels is consistent with other studies(49-51). For example, Dini et al. found 
prospectively in a population with reduced to mid-range LVEF a negative relation between 
TAPSE and NT-proBNP markers, and an increase in prognostic information to other clinical 
and echocardiographic variables used in HF risk stratification(50). Further, in a pediatric 
population with pulmonary arterial hypertension, with no signs of LV dysfunction, RV-PA 
decoupling was correlated with increase of NT-proBNP levels(51).  Together, these findings 
emphasize the need to account for afterload when assessing RV function. Whether it adds 
prognostic significance to patients with HF is still uncertain. 
 
 
Conclusion 
 
Our study reinforces the value of studying right heart and pulmonary circulation in 
patients with left HF. TAPSE/PASP ratio is an easy tool to assess RV length/force 
relationship and have important clinical significance. It was associated with validated 
prognostic markers in HF such as NT-proBNP, LVEF and E/e’ ratio. In addition, it 
outperformed isolated TAPSE in identifying patients who did not respond to CRT. Whether 
it adds on prognostic information to PASP is still unclear. 
 
 
Study limitations 
 
 Our main limitations were the small number of patients included and the exclusive 
non-invasive assessment of RV function. The retrospective nature of this study and the 
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difficulty in fully visualizing the RV in some patients resulted in significant losses of data and 
make it more prone to be influenced by bias and confounding factors. For complete RV 
assessment, right heart catheterization (for hemodynamics evaluation) and cardiac 
magnetic resonance (for function and chamber size) are considered the gold standard both 
are costly and with limited availability. Moreover, the first is an invasive exam and the 
second is not feasible after CRT implantation. Echocardiography remains the most 
accessible tool to evaluate cardiac function in daily practice and is highly validated. The 
correlation of non-invasive estimates with invasive measurements has been shown before 
to be accurate in HF with reduced LVEF patients(27).  Furthermore, PASP is also influenced 
by PVR, which might not be a direct consequence of cardiac dysfunction. However, since 
both pulmonary congestion and PVR will deleteriously affect afterload in chronic HF, hence 
the prognostic significance seems to be retained.  
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Appendix 
Tables 
 
Table 1 – Clinical features of the studied population according to TAPSE/PASP 
tertiles 
Variable  Overall (n=69) 1sttertile (n=23) 2ndtertile (n=24) 3rdtertile (n=22) p value 
TAPSE/PASP, mm/Hg  0.48±0.24 0.26±0.06 0.45±0.06 0.75±0.21 *, β,† 
Age (years)  70±10 71±10 70±10 71±10 ns 
Male, (%)  69.6 73.9 58.3 77.3 ns 
BMI (kg/m2)  27.1±9.1 28.2±16.1 27.3±4.2 26.2±3.6 ns 
Diabetes, (%)  42.0 34.8 66.7 22.7 ns 
Hypertension, (%)  79.7 73.9 79.2 86.4 ns 
Dyslipidemia, (%)  73.9 82.6 62.5 77.3 ns 
Smoke, (%)       
activesmokers 7.2 8.7 4.2 9.1 ns 
ex-smokers 30.4 34.8 33.3 22.7 ns 
AtrialFibrillation, (%)  56.5 60.9 54.2 54.5 ns 
COPD, (%)  20.3 21.7 20.8 18.2 ns 
Stroke, (%)  10.1 8.7 8.3 13.6 ns 
Ischemicetiology, (%)  50.7 52.2 54.2 45.5 ns 
NYHA, (%)       
II 23.2 13.0 29.2 27.3 ns 
III 76.8 87.0 70.8 72.7 ns 
IV 0.0 0.0 0.0 0.0 ns 
Left bundle block, (%)  79.3 76.5 72.7 89.5 ns 
QRS duration (ms)  162.8±27.6 163.6±25.9 167.5±23.4 156.8±33.7 ns 
Medication, (%)       
ACEIs/ARBs 
 
82.6 73.9 87.5 86.4 ns 
     Beta-blocke 84.1 91.3 79.2 81.8 ns 
MRAs 
 
49.3 56.5 37.5 54.5 ns 
Diuretics 
 
89.9 91.3 91.7 86.4 ns 
Statins 
 
73.9 73.9 66.7 81.8 ns 
Amiodarone 
 
13.0 17.4 8.3 13.6 ns 
Digitalis 
 
24.6 21.7 25.0 27.3 ns 
Ivabradine 
 
2.9 4.3 0.0 4.5 ns 
Antiplatelets 
 
66.7 73.9 54.2 72.7 ns 
Anticoagulants 
 
46.4 43.5 50.0 45.5 ns 
Insulin 18.8 13.0 41.7 0.0 ns 
Hemoglobin, g/dL  13.1±1.8 12.4±1.5 13.0±1.8 13.8±1.8 β 
GFR, mL/min/1.73 m2  61.1±23.9 59.3±25.9 59.6±27.2 64.7±17.9 ns 
GFR < 60, (%)  50.7 60.9 50.0 40.9 ns 
NT-proBNP, pg/mL  
(min-max) 
 6619±11964 7391 
(2407.5-11259.0) 
1887 
(761.2-6647.0) 
1400 
(655.1-3881.0) 
*, β 
CRT-D, (%)  59.4 6.5 58.3 77.3 ns 
Responder NYHA, (%)  46.4 39.1 45.8 54.5 ns 
Responder LVEF, (%)  69.6 52.2 70.8 86.4 *, β,† 
Data are presented as mean ± standard deviation or n (%).  
Abbreviation: ACEIs, angiotensin-covering enzyme inhibitors; BMI, body mass index; COPD; chronic obstructive pulmonary disease; CRT, 
cardiac resynchronization therapy; GFR, glomerular filtration rate; LVEF, left ventricular ejection fraction; MRAs, mineralocorticoid receptor 
antagonist; ns, not significat; NT-proBNP, N-terminal pro-B-type natriuretic peptide.  NYHA, New York Heart Association; PASP, estimated 
pulmonary artery systolic pressure. 
Statistical significance between groups were calculated using ANOVA tests: 1sttertile vs 2ndtertile (*p<0.05), 1sttertile vs 3rdtertile (β p<0.05), 
2ndtertile vs 3rdtertile († p<0.05). ns means not-significant. 
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Table 2 - Echocardiographic characteristics of the studied population according 
to TAPSE/PASP tertiles 
Variable  Overall(n=69) 1sttertile(n=23) 2ndtertile(n=24) 3rdtertile(n=22) p value 
RA area, cm2  19.7±6.6 21.0±6.6 20.1±7.0 17.8±5.8 ns 
RVEDA, cm2  17.6±5.3 19.8±6.6 17.9±3.7 14.9±3.8 β 
RVESA, cm2  10.8±4.9 13.7±6.0 10.6±2.7 7.7±3.0 β 
LA area, cm2  28.5±7.5 30.6±8.6 29.5±6.5 25.3±6.5  β, † 
LVESD, mm  51.0±9.7 53.1±10.5 49.5±8.7 50.1±9.9 ns 
LVEDD, mm  60.2±9.5 62.6±9.0 58.1±7.3 60.6±11.9  ns 
PASP (mmHg)  38.8±14.5 52.8±12.5 36.8±9.0 26.2±6.9 *, β, † 
TAPSE, mm  16.1±4.0 13.4±3.2 16.2±3.4 18.9±3.4 β 
TAPSE/PASP, mm/Hg  0.48±0.24 0.26±0.06 0.45±0.06 0.75±0.21 *, β, † 
LVEF, %  26.4±7.1 23.8±6.2 28.5±7.3 27.0±7.3 * 
E/e’ ratio  12.5±4.6 13.5±4.4 15.7±4.4 9.8±3.4 β, † 
S’ cm/s  9.5±2.6 7.9±2.2 9.5±2.1 11.3±2.4 † 
RV diameter, mm  39.1±10.2 43.1±8.8 38.5±10.6 35.2±10.0 *, β 
PVR, woods units  2.60±1.0 3.4±1.1 2.4±0.9 1.9±0.4 *, β, † 
Data are presented as mean ± standard deviation.  
Abbreviation:  E/E’, early diastolic transmitral flow velocity to averaged annular early diastolic velocity ratio; ePSAP:  estimated 
pulmonary systolic artery pressure; LA: left atrial; LVEF: left ventricular ejection fraction; LVEDV, LV end-diastolic diameter; LVESV, 
LV end-systolic diameter; PVR: pulmonary vascular resistance; RA: right atrial; RV: right ventricle; RVEDA,  RV end-diastolic area; 
RVESA, RV end-systolic area; S’, annular systolic velocity; TAPSE: tricuspid annular plane systolic excursion. 
Statistical significance between groups were calculated using ANOVA tests: 1sttertile vs 2ndtertile (*p<0.05), 1sttertile vs 3rdtertile (β 
p<0.05), 2ndtertile vs 3rdtertile († p<0.05). ns means not-significant. 
 
 
Table 3 – Survival analysis for echocardiographic variables 
 Univariableanalysis  Multivariableanalysis 
Variable HazardRatio 95% 
ConfidenceInterval 
Pvalue  HazardRatio 95% 
ConfidenceInterval 
P value 
PASP 1.029 1.006 to 1.052 0.012  1.019 0.994 to 1.045 0.025 
TAPSE 1.011 0.874 to 1.170 0.883  1.016 0.883 to 1.170 0.820 
TAPSE/PASP 2.637 0.181 to 38.33 0.478  2.077 0.131 to 32.91 0.604 
Data were calculated using Cox regression model. PASP, TAPSE and TAPSE/PASP correspond to baseline data before CRT. Multivariable 
models included adjustment for age, sex, log(NT-proBNP).  Abbreviation ePSAP: estimated pulmonary systolic artery pressure; TAPSE: tricuspid 
annular plane systolic excursion. 
 
 
Figures 
 
 
Figure 1 - Pearson’s correlation analysis between TAPSE/PASP and log-transformed 
NT-proBNP before CRT. Solid line represents its linear relationship, with 95% 
confidence interval limited by dashed lines. p<0.05 was considered significant. 
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Figure 2 - Survival curves according to PASP, TAPSE and TAPSE/PASP ratio for 
primary outcome all-cause of death. Cut-off values represent data median for each 
variable. Inside upper charts represent overall survival 12 and 60 month after CRT. P-
values were obtained by log-rank (Mantel–Cox) significance (*p<0.05 was considered 
significant; ns means not-significant). 
 
 
Figure 3 - Percentage of patients with improved LVEF response by PASP, TAPSE 
and TAPSE/PASP (categorized by median) 6 to 12 months after CRT.  Patients with 
an increase of LVEF≥5% after CRT were considered to have an improved response. 
Small inset indicates median values for the variables presented. Number of patients 
in each subgroup is indicated inside bars. P-values were calculated with use of the 
chi-square test (*P<0.05 was considered significant, ns means not-significant). 
0 20 40 60 80 100
0.0
0.5
1.0
Time, months
Su
rv
iv
al
 p
ro
ba
bi
lty
(12-month)
All
 PASP≤36 
 PASP>36
93.33%
98.36%
88.14%
(60-month)
64.82%
71.26%
57.94%
Survival rateNo. of
 patients
120
61
59*
PASP > 36 mmHg
PASP ≤ 36 mmHg
All
0 20 40 60 80 100
0.0
0.5
1.0
Time, months
Su
rv
iv
al
 p
ro
ba
bi
lty
(12-month)
All
TAPSE≥ 14
TAPSE < 14
95.92%
97.40%
90.48%
(60-month)
72.96%
73.97%
68.93%
Survival rateNo. of
 patients
98
77
21
ns
TAPSE < 14 mm
TAPSE ≥ 14 mm
All
0 20 40 60 80 100
0.0
0.5
1.0
Time, months
Su
rv
iv
al
 p
ro
ba
bi
lty
(12-month)
All
TAPSE/PASP ≥ 0.43 
TAPSE/PASP < 0.43
95.71%
100.0%
91.43%
(60-month)
64.66%
50.41%
80.00%
Survival rateNo. of
 patients
70
35
35ns
TAPSE/PASP ≥ 0.43 mm/mmHg
TAPSE/PASP < 0.43 mm/mmHg
All
A B C
PASP TAPSE TAPSE/PASP
0
50
100
%
 p
at
ie
nt
s 
w
ith
 L
EV
F 
im
pr
ov
em
en
t  
Below median
Above median
**
27 7 15 20 7 17
ns
Median
ePASP = 36 mmHg
TAPSE = 17 mm
TAPSE/ePASP = 0.43 mm/mmHg
 13 
 
Figure 4 - Mortality rate by PASP, TAPSE and TAPSE/PASP (categorized by median) 
6 to 12 months after CRT.  Small inset indicates median values for the variables 
presented. Number of patients in each subgroup is indicated inside bars. P-values 
were calculated with use of the chi-square test (*P<0.05 was considered significant, 
ns means not-significant). 
 
Figure 5 - ROC curves for TAPSE, PASP and TAPSE/PASP to identify unimproved 
LVEF (defined as LVEF < 5%) after CRT. Area under the curve (AUC); 95% 
confidence interval (CI). p<0,05 was considered significantly different from dotted line 
(AUC=0.5) 
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Supplementary data 
 
Table 4 – Hazard rations for secondary outcomes 
 Univariable analysis  Multivariable analysis 
Variable Hazard 
Ratio 
95% Confidence 
Interval 
P value  Hazard 
Ratio 
95% Confidence 
Interval 
P value 
NYHA improvement -0.025 -0.050 to 0.001 0.058  -0.018 -0.050 to 0.014 0.262 
LVEF improvement -0.022 -0.05 to 0.005 0.113  0.006 -0.031 to 1.045 0.765 
Primary outcome was all cause death; secondary outcome was (NYHA and LVEF improvement). Data represent unadjusted and adjusted odds 
ratios (ORs) for estimated pulmonary artery systolic pressure (ePSAP) as a predictor of any improvement of left ventricular ejection fraction 
(LVEF) superior to 5% and improvement of NYHA between the baseline and 6 to 12-month echocardiograms or hazard ratios (HRs) for mortality. 
Multivariable models included adjustment for age, sex, log(NT-proBNP). 
 
 
 
Figure 6 - Survival curves according to absence or presence of pulmonary hypertension 
(PH), defined as PASP >40 mmHg, for primary outcome of all-cause death in all patients. 
Inside upper chart represents overall survival 12 and 60 month after CRT. P-values were 
obtained by log-rank (Mantel–Cox) significance (*p<0.05 was considered significant). 
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Figure 7- Survival curves according to absence or presence of pulmonary hypertension 
(PH), defined as PASP >40 mmHg, for primary outcome of all-cause death in patients with 
glomerular filtration rate (GFR) equal or higher (panel A), or lower (panel B) than 
60mL/min/1.73m2. Inside upper charts represent overall survival 12 and 60 month after 
CRT.  p values were obtained by log-rank (Mantel–Cox) significance (*P<0.05 was 
considered significant; ns means not-significant). 
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